Australia Markets close in 5 hrs 29 mins

Starpharma Holdings Limited (SPL.AX)


ASX - ASX Delayed price. Currency in AUD
Add to watchlist
0.795+0.005 (+0.633%)
As of 10:09AM AEST. Market open.
Full screen
Previous close0.790
Open0.795
Bid0.790 x
Ask0.795 x
Day's range0.795 - 0.795
52-week range0.590 - 0.880
Volume20,355
Avg. volume223,838
Market cap293.43M
Beta0.64
PE ratio (TTM)-12.62
EPS (TTM)-0.06
Earnings dateN/A
Dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est0.94
  • Business Wirelast month

    Starpharma Sells Agrochemicals Business to Agrium for $35M

    MELBOURNE, Australia--(BUSINESSWIRE)-- Starpharma Holdings Ltd (ASX: SPL, OTCQX: SPHRY) today announced that it has completed a transaction to sell its agrochemicals and Priostar® business (Starpharma Agrochemicals) to Agrium, Inc., (Agrium) (NYSE: AGU, TSE: AGU) for A$35 million in cash consideration. The Starpharma Agrochemical business will be operated by Agrium’s wholly-owned subsidiary, Loveland Products, Inc. This business is independent of Starpharma’s DEP® and VivaGel® products and related intellectual property portfolios.

  • Business Wire3 months ago

    Ansell Launches VivaGel® Condom in Canada

    MELBOURNE, Australia--(BUSINESSWIRE)-- Starpharma Holdings Ltd (ASX:SPL, OTCQX:SPHRY) is pleased to announce the VivaGel ® condom has been launched in Canada by Ansell (ASX:ANN) under the LifeStyles ® ...

  • Business Wire6 months ago

    VivaGel® BV granted QIDP and Fast Track designation by US FDA

    MELBOURNE, Australia--(BUSINESSWIRE)-- Starpharma Holdings Ltd (ASX:SPL, OTCQX:SPHRY) today announced it has been granted Qualified Infectious Disease Product (QIDP) and Fast Track designation for VivaGel® BV by the US Food and Drug Administration (FDA). QIDP and Fast Track designations were granted independently for both the VivaGel® BV treatment and prevention indications for bacterial vaginosis (BV). This positive development recognises the high unmet medical need in the management of BV and the potential of VivaGel® BV to address that need for both treatment and prevention of recurrent BV, markets estimated to be worth in excess of US$1 billion globally.